CARLSBAD, Calif., May 15, 2024 /PRNewswire/ — DCN Dx, a leading contract research organization for in vitro diagnostics, today acknowledges the FDA’s Emergency Use Authorization (EUA) of the WELLlife™ COVID-19/Influenza A&B Test, developed by Wondfo USA. This important authorization will enable healthcare professionals to differentiate rapidly between COVID-19 and influenza infections, enhancing patient care at the point-of-care.

How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them.

A filter made from yeast encapsulated in hydrogels can quickly absorb lead as water flows through it.

The approval allows women to self-collect vaginal specimens for HPV testing in a health care setting, which could include non-traditional locations such as a retail pharmacy or mobile clinic.

Butterfly Network (NYSE:BFLY) announced today that it launched its first specialty product, the iQ+ Bladder portable ultrasound.

Atraverse Medical announced today that the FDA cleared its Hotwire radiofrequency guidewire left-heart access device.